ESR1 and breast cancer: While these three subtypes above can have favorable clinical outcomes due to their responsiveness to the targeted therapies, poor prognosis is usually observed within a major subdivision of the fourth breast cancer subtype referred to as TNBC with a negative expression of ER, PR, or HER2 due to lack of targeted treatment options for this patient population (3–5, 11–13).